Lupus & antiphospholipid syndrome

Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry‐Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus

Arthritis RheumatolPublished Prospective cohort study

Authors' conclusion

Ancestry appears central to the immunologic and clinical heterogeneity in SLE.

Study context

Population
Patients with active systemic lupus erythematosus (SLE) refractory to standard therapy, multiethnic UK cohort, British Isles Lupus Assessment Group (BILAG) Biologics Register110 assessed for rituximab response
Participants
213 patients
Exposure
Gene expression clusters by ancestry and response to rituximab
Outcome
Response to first-cycle rituximab (BILAG 2004 disease activity)
Follow-up
6 months from treatment start
Methodological detailsregistry-based (BILAG Biologics Register), multiethnic, hierarchical clustering
  • Registry-based (BILAG Biologics Register)
  • Multiethnic
  • Hierarchical clustering

Main finding

As reported in the abstract

Response to rituximab by gene expression cluster · 6 months
Non-European ancestry: 3 distinct clusters with stratified responses to rituximab, not explained by sociodemographic and clinical variables; lowest in interferon-low, neutrophil-high cluster, highest in cluster with high expression across all signatures
P < 0.001

Observational data: associations, not effects.

Further findings

Interferon gene expression scores by ancestry · baseline

Lower in European ancestry than in all other ancestry groups
Relationship of interferon scores with plasmablast, neutrophil, myeloid lineage, inflammation and erythropoiesis scores differed between European and non-European ancestries

Autoantibodies

In both ancestral groups, interferon-high clusters associated with U1 RNP/Sm antibodies

Original publication

Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry‐Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus. Arthritis Rheumatol. Published 22 March 2023. doi:10.1002/art.42404

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.